Epirubicin
Recurrent Waldenstrom Macroglobulinemia
Celldex TherapeuticsPhase 2Dormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Recurrent Waldenstrom Macroglobulinemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Celldex Therapeutics | Phase 2 | BB |
Temsirolimus National Cancer Institute (NCI) | Phase 2 | BB |
Carfilzomib University of Washington | Phase 2 | B |
Idelalisib University of Maryland, Baltimore | Phase 2 | CCC |
Nivolumab David Bond, MD | Phase 1/2 | CCC |
Selinexor Barbara Ann Karmanos Cancer Institute | Phase 1/2 | CCC |
Umbralisib Yazeed Sawalha | Phase 2 | CC |
q702 Mayo Clinic | Phase 1 | CC |
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →